Duration of Protection From Pneumonia After Pneumococcal Vaccination in Hemodialysis Patients (DOPPIO): Protocol for a Prospective Multicenter Study

• Published in: JMIR research protocols Vol. 12; p. e45712
• Main Authors: Mellinghoff, Sibylle, von Gersdorff, Gero, Bruns, Caroline, Albus, Kerstin, Dimitriou, Vassiliki, Steinbach, Angela, Schaller, Mathias, Vehreschild, Jörg Janne, Cornely, Oliver A, Liss, Blasius Janusch
• Format: Journal Article
• Language: English
• Published: Canada JMIR Publications 12.07.2023
• Subjects: Antibodies; Chronic illnesses; Hemodialysis; Immunization; Immunocompetence; Immunology; Infections; Informed consent; Kidney diseases; Kidney transplants; Mortality; Patients; Physicians; Pneumonia; Protocol; Site selection; Streptococcus infections; Vaccines; Germany; clinical trial; dialysis; kidney; vaccine; pneumonia; infectious disease; hemodialysis; pulmonary; communicable disease; pneumococcal; Streptococcus pneumoniae; vaccination
• ISSN: 1929-0748; 1929-0748
• DOI: 10.2196/45712

Pneumonia is a leading cause of death in patients with end-stage chronic kidney disease treated with dialysis. Current vaccination schedules recommend pneumococcal vaccination. However, this schedule disregards findings of rapid titer decline in adult hemodialysis patients after 12 months. The primary objective is to compare pneumonia rates between recently vaccinated patients and patients vaccinated more than 2 years ago. As an exploratory objective, antipneumococcal antibody titers in hemodialysis patients will be determined as a function. Factors influencing antibody kinetics will be identified. Within this prospective multicenter study, we aim to compare 2 strata of vaccinated patients: those recently vaccinated and those vaccinated more than 2 years ago. A total of 792 patients will be enrolled. Twelve partner sites (within the German Centre for Infection Research [DZIF]) with allocated dialysis practices participate in this study. All dialysis patients who are vaccinated against pneumococcal infection in accordance with Robert Koch Institute guidelines prior to enrollment will be eligible. Data on baseline demographics, vaccination history, and underlying disease will be assessed. Pneumococcal antibody titers will be determined at baseline and every 3 months for 2 years. DZIF clinical trial units coordinate titer assessment schedules and actively follow-up on study patients for 2-5 years after enrollment, including validation of end points of hospitalization, pneumonia, and death. The study has enrolled 792 patients and the last follow-up has been completed. Currently, the statistical and laboratory analyses are ongoing. Results will increase physician adherence to current recommendations. Establishing a framework for the efficient evaluation of guideline recommendations through a combination of routine and study data will inform the evidence base for future guidelines. ClinicalTrials.gov NCT03350425; https://clinicaltrials.gov/ct2/show/NCT03350425. DERR1-10.2196/45712.